Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Recurrence 2Multiple Myeloma 2Lymphoma, B-Cell 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Congenital Abnormalities 1Burkitt Lymphoma 1

Interventions

Cytarabine 34Busulfan 17Cyclophosphamide 16fludarabine phosphate 15Peripheral Blood Stem Cell Transplantation 13Filgrastim 13Etoposide 13Idarubicin 12Mitoxantrone 9Cyclosporine 9Antilymphocyte Serum 9Methotrexate 8Daunorubicin 8Whole-Body Irradiation 6Radiotherapy 6Tacrolimus 5Cord Blood Stem Cell Transplantation 5Clofarabine 5Mycophenolic Acid 4Methylprednisolone 4Melphalan 4Gemtuzumab 4Flow Cytometry 4Arsenic Trioxide 4aldesleukin 3Topotecan 3Imatinib Mesylate 3Cytogenetic Analysis 3Cyclosporins 3Bortezomib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Leukemia, Erythroblastic, Acute × Proteasome Inhibitors × Clear all
NCT02030405 2019-04-05

Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Stanford University

Phase 2 Terminated
4 enrolled 10 charts
Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡